Abstract:Background: Eradication rate of standard triple therapy for Helicobacter pylori(H.pylori) infection is decreasing recently.It is urgent to look for a novel,safe and effective regimen.Aims: To assess the efficacy and safety of bismuth-clarithromycin-containing quadruple regimen as a primary therapy for H.pylori eradication.Methods: A total of 120 H.pylori-infected patients with non-ulcer dyspepsia diagnosed by gastroscopy were enrolled and randomly assigned into three groups: 7-day triple therapy(omeprazole 20 mg bid,amoxicillin 1000 mg bid and clarithromycin 500 mg bid for 7 days),7-day quadruple therapy(7-day triple therapy plus bismuth potassium citrate 220 mg bid for 7 days) and 2-week quadruple therapy(7-day quadruple therapy for 2 weeks).At least four weeks after the end of treatment,H.pylori eradication was assessed by 13C-urea breath test.H.pylori strains isolated were tested for clarithromycin,metronidazole and amoxicillin resistance.Results: A total of 115 patients completed the study.H.pylori eradication rates by intention-to-treat(ITT) analysis in 7-day triple therapy,7-day quadruple therapy,2-week quadruple therapy were 70.0%,75.0%,90.0%,respectively;by per-protocol(PP) analysis were 73.7%,76.9%,94.7%,respectively.The eradication rate in 2-week quadruple therapy was significantly higher than that in 7-day triple therapy by both ITT and PP analysis(P<0.05),and was significantly higher than that in 7-day quadruple therapy by PP analysis(P=0.026).No significant difference in eradication rate by ITT and PP analysis was found between 7-day triple therapy and 7-day quadruple therapy.The resistance rates of H.pylori to clarithromycin,metronidazole and amoxicillin were 24.2%,48.3%,0%,respectively.The eradication rates of 7-day triple therapy,7-day quadruple therapy and 2-week quadruple therapy in patients with clarithromycin-resistant strains increased stepwisely(37.5%,55.6%,80.0%),but not reached statistical significance.Except one patient in 2-week quadruple therapy could not complete the course of treatment due to skin allergy,other patients in all three groups had slight and similar side-effects and all were well tolerated.Conclusions: Two-week bismuth-clarithromycin-containing quadruple therapy can increase the eradication rate of H.pylori with safety,and could be used as the first line eradication regimen.

Comparison of the Efficacy of Triple Versus Quadruple Therapy on the Eradication of Helicobacter Pylori and Antibiotic Resistance.

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

The evaluation of the efficacy of pantoprazole-based triple and quadruple therapy in Helicobacter pylori eradication

Non-bismuth Quadruple Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication: a Randomized Controlled Study

Is Tailored Therapy Based on Antibiotic Susceptibility Effective ? a Multicenter, Open-Label, Randomized Trial

Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.

Study of 4-,5- and 7-Day Pantoprazole Quadruple Therapy Regimens in the Treatment of Helicobacter Pylori Infection

A Comparison of Doxycycline and Amoxicillin Containing Quadruple Eradication Therapy for Treating Helicobacter pylori-Infected Duodenal Ulcers: A Multicenter, Opened, Randomized Controlled Trial in China

Efficacy of quadruple therapy and Lactobacillus acidophilus for Helicobacter pylori eradication

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

A Clinical Study of Proton Pump Inhibitor-containing Quadruple Regimen as First-line Therapy for Helicobacter pylori Eradication

Evaluation of Bismuth-clarithromycin-containing Quadruple Therapy for Initial Helicobacter pylori Eradication

Different Duration of Quadruple Therapy for First-line Helicobacter Pylori Eradication Treatment——A Randomized,Controlled Trial

Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori

Comparison of the Efficacy of 1‐day High‐dose Quadruple Therapy Versus 7‐day Triple Therapy for Treatment of Helicobacter Pylori Infection

Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori

Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial

Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection

Clinical Study on Berberine, Amoxicillin, Lansoprazole, Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in 283 Patients

Comparison of the Efficacy Between the Dual Therapy of Tegoprazan and the Quadruple Therapy of Tegoprazan: A Randomized, Controlled, Multicenter Study

A randomized controlled study of 5- and 7-d pantoprazole quadruple regimens for Helicobacter pylori eradication